A rational targeted therapy for platinum-resistant small-cell lung cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia–mutated and rad3-related) inhibitor berzosertib.

Original languageEnglish (US)
Pages (from-to)453-456
Number of pages4
JournalCancer Cell
Volume39
Issue number4
DOIs
StatePublished - Apr 12 2021

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'A rational targeted therapy for platinum-resistant small-cell lung cancer'. Together they form a unique fingerprint.

Cite this